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Abstract
Introduction: The use of topiramate has increased in recent years. It is now used by various
specialties to treat a wide range of medical conditions. A small number of case reports describe
psychosis as an adverse event of topiramate but most are in patients being treated for epilepsy and
none describe a family history of this side effect.
Case presentation: We present a case report of topiramate-induced psychosis in a patient with
familial essential tremor, whose sister also developed this same adverse effect.
Conclusion: Physicians need to be aware of psychosis as a rare but debilitating side effect of this
drug. Several predictors have been identified and a careful history, including family history, needs
to be obtained prior to initiation of therapy to stratify the risk.
Introduction
Topiramate is a relatively new anti-epileptic drug. There is
increasing interest in its use in a wide range of applica-
tions and therefore its use and side effects have great
importance to general and specialist physicians. It is
licensed in the United Kingdom for the management of
epilepsy and migraine prophylaxis and is used 'off-label'
in the management of essential tremor, alcohol depend-
ence, bulimia nervosa and mood disorders [1,2].
We present a case report of an unusual but serious side
effect of topiramate. There are a small number of case
reports describing topiramate-induced psychosis but the
majority are in patients being treated for epilepsy [3-5]
and none have described a family history of this side
effect.
Case presentation
A 46-year-old man presented to the emergency medical
assessment unit with an 8-day history of visual hallucina-
tions and paranoid delusions. He had a past medical his-
tory of essential tremor that was being treated with
topiramate. In the past he had tried propranolol and
labetalol with little benefit. There was no past history of
psychiatric symptoms. He had consumed no alcohol in
the previous 3 months but had in the past been drinking
eight units of alcohol per day to help control his tremor.
No cause for the altered mental state was apparent on clin-
ical examination and initial investigations. The following
blood tests were performed and were all normal: full
blood count, urea, creatinine, electrolytes, liver function
tests, vitamin B12 level, thyroid function tests, autoim-
mune screen, syphilis serology and blood cultures. On the
mini-mental state examination he scored 26/30. A com-
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puter tomography scan of the brain and a lumbar punc-
ture were performed and both were normal. There was no
evidence of delirium tremens or Wernicke's encephalopa-
thy.
After a discussion with his father on day five of the admis-
sion we were told that the onset of the symptoms occurred
2 days after an increase in the dose of topiramate. The
patient had commenced topiramate 3 months previously
and reached a dose of 75 mg twice a day. The dose had
been increased in 25 mg increments. Since the increase in
the dose of topiramate and while in the ward he was dis-
orientated as to time and place, had visual and auditory
hallucinations and his short-term registration and recall
were impaired. He was unable to remember any events
occurring after the day the dose of topiramate was
increased. The topiramate was stopped and over the fol-
lowing few days he gradually improved. A week after dis-
continuing the topiramate he was back to his normal self
and was discharged. Unfortunately his tremor returned.
After discussing the diagnosis of topiramate-induced psy-
chosis with the patient he told us that his sister had devel-
oped visual hallucinations when commenced on
topiramate 25 mg twice a day for migraine prophylaxis,
and that these had resolved on discontinuing the treat-
ment. She also had no past history of psychiatric symp-
toms.
Discussion
Topiramate was originally discovered as an oral hypogly-
caemic, later used as an anticonvulsant and is now used as
an adjunct to numerous therapies. It is a derivative of
monosaccharide D-fructose and the various mechanisms
of action include: inhibition of sodium conductance;
decreased frequency of generated action potentials;
enhanced gamma-aminobutyric acid activity; inhibition
of the alpha-amino-3-hydroxy-5-methylisoxazole-4 pro-
pionic acid subtype glutamate receptor; and weak inhibi-
tion of carbonic anhydrase [1].
The use of topiramate is now well established in the man-
agement of epilepsy (both as monotherapy and adjunc-
tive therapy), migraine prophylaxis and essential tremor.
There is interest in using it to promote abstinence in alco-
hol-dependent individuals and in the treatment of
bulimia nervosa and mood disorders [1,2]. Common
adverse reactions include metabolic acidosis, ataxia, con-
centration difficulty, confusion, dizziness, fatigue, par-
esthesiae, somnolence, disturbance of memory,
depression, agitation, psychomotor slowness and speech
disturbance.
The true prevalence of topiramate-induced psychosis is
not well established. Although there have only been a few
case reports of topiramate-induced psychosis, the post-
marketing anti-epileptic drug survey group found the inci-
dence to be 1.5% in 596 patients. The risk of this side
effect may be greater in the general population as studies
of topiramate exclude patients with past psychiatric his-
tory, and past psychiatric history is the strongest predictor
for psychiatric adverse events [6]. However, the risk of
developing psychosis in patients with epilepsy is 6 to 12
times higher than in patients without epilepsy, therefore
the risk of developing psychosis in patients using topira-
mate for familial essential tremor may actually be lower
than 1.5% (see [6]). There have been several other poten-
tial predictors of psychiatric adverse events investigated,
such as starting dose and titration schedule [5]. Our
patient received the standard dose and titration, starting at
25 mg/day and increased in increments of 25 mg.
Our case report is unique in that a family member (the
patient's sister) experienced the same side effect of topira-
mate-induced psychosis and no other risk factors were
identified. Two hypotheses to explain this connection are
that there is either an inherited abnormality of topiramate
metabolism or a familial predisposition to psychosis.
Both have implications for the patient's daughter, who
has also been diagnosed with essential tremor at the age
of 15.
Conclusion
Topiramate is being increasingly prescribed Physicians
need to be aware of psychosis as a rare but debilitating
side effect. Several predictors have been identified and a
careful history, including family history, needs to be
obtained prior to initiation of therapy to stratify the risk.
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